Combination Treatments with the PKC Inhibitor, Enzastaurin, Enhance the Cytotoxicity of the Anti-Mesothelin Immunotoxin, SS1P

PLoS ONE

Volumn 8, Issue 10, 2013, Pages

  Mattoo, Abid R ^a   Pastan, Ira ^a   FitzGerald, David ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

12 (2 CYANOETHYL) 6,7,12,13 TETRAHYDRO 13 METHYL 5 OXOINDOLO[2,3 A]PYRROLO[3,4 C]CARBAZOLE; CASPASE 3; CASPASE 7; ENZASTAURIN; IMMUNOTOXIN; IMMUNOTOXIN SS1P; PROTEIN BCL 2; PROTEIN KINASE B; PROTEIN KINASE C; PROTEIN MCL 1; SOTRASTAURIN; UNCLASSIFIED DRUG;

APOPTOSIS; ARTICLE; CELL DEATH; CELL MEMBRANE RESISTANCE; CELL SURVIVAL; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; DRUG CYTOTOXICITY; DRUG POTENTIATION; ENZYME ACTIVATION; ENZYME INHIBITION; HUMAN; HUMAN CELL; IC 50; MONOTHERAPY; PROTEIN DEPLETION; PROTEIN SYNTHESIS; SIGNAL TRANSDUCTION;

ANTIBODIES, MONOCLONAL; APOPTOSIS; BLOTTING, WESTERN; CELL LINE, TUMOR; COMBINED MODALITY THERAPY; DRUG SYNERGISM; GPI-LINKED PROTEINS; HUMANS; INDOLES; INHIBITORY CONCENTRATION 50; PROTEIN KINASE C BETA;

EID: 84885120931     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0075576     Document Type: Article

References (39)

1. Podar K, Raab MS, Chauhan D, Anderson KC, (2007) The therapeutic role of targeting protein kinase C in solid and hematologic malignancies. Expert Opin Investig Drugs 16: 1693-1707.
2. Mochly-Rosen D, Das K, Grimes KV, (2012) Protein kinase C, an elusive therapeutic target? Nat Rev Drug Discov 11: 937-957.
3. Graff JR, McNulty AM, Hanna KR, Konicek BW, Lynch RL, et al. (2005) The protein kinase Cbeta-selective inhibitor, Enzastaurin (LY317615.HCl), suppresses signaling through the AKT pathway, induces apoptosis, and suppresses growth of human colon cancer and glioblastoma xenografts. Cancer Res 65: 7462-7469.
4. Biswas DK, Dai SC, Cruz A, Weiser B, Graner E, et al. (2001) The nuclear factor kappa B (NF-kappa B): a potential therapeutic target for estrogen receptor negative breast cancers. Proc Natl Acad Sci U S A 98: 10386-10391.
5. Naylor TL, Tang H, Ratsch BA, Enns A, Loo A, et al. (2011) Protein kinase C inhibitor sotrastaurin selectively inhibits the growth of CD79 mutant diffuse large B-cell lymphomas. Cancer Res 71: 2643-2653.
6. Liu XY, Pop LM, Vitetta ES, (2008) Engineering therapeutic monoclonal antibodies. Immunol Rev 222: 9-27.
7. Weiner LM, Surana R, Wang S, (2010) Monoclonal antibodies: versatile platforms for cancer immunotherapy. Nat Rev Immunol 10: 317-327.
8. Weldon JE, Pastan I, (2011) A guide to taming a toxin-recombinant immunotoxins constructed from Pseudomonas exotoxin A for the treatment of cancer. FEBS J 278: 4683-4700.
9. FitzGerald DJ, Wayne AS, Kreitman RJ, Pastan I, (2011) Treatment of hematologic malignancies with immunotoxins and antibody-drug conjugates. Cancer Res 71: 6300-6309.
10. Pastan I, Hassan R, FitzGerald DJ, Kreitman RJ, (2007) Immunotoxin treatment of cancer. Annu Rev Med 58: 221-237.
11. Hwang J, Fitzgerald DJ, Adhya S, Pastan I, (1987) Functional domains of Pseudomonas exotoxin identified by deletion analysis of the gene expressed in E. coli. Cell 48: 129-136.
12. Barger JF, Gallo CA, Tandon P, Liu H, Sullivan A, et al. (2013) S6K1 determines the metabolic requirements for BCR-ABL survival. Oncogene 32: 453-461.
13. Mattoo AR, FitzGerald DJ, (2013) Combination treatments with ABT-263 and an immunotoxin produce synergistic killing of ABT-263-resistant small cell lung cancer cell lines. Int J Cancer 132: 978-987.
14. Traini R, Ben-Josef G, Pastrana DV, Moskatel E, Sharma AK, et al. (2010) ABT-737 overcomes resistance to immunotoxin-mediated apoptosis and enhances the delivery of pseudomonas exotoxin-based proteins to the cell cytosol. Mol Cancer Ther 9: 2007-2015.
15. Fitzgerald DJ, Moskatel E, Ben-Josef G, Traini R, Tendler T, et al. (2011) Enhancing immunotoxin cell-killing activity via combination therapy with ABT-737. Leuk Lymphoma 52Suppl 2: 79-81.
16. Du X, Xiang L, Mackall C, Pastan I, (2011) Killing of resistant cancer cells with low Bak by a combination of an antimesothelin immunotoxin and a TRAIL Receptor 2 agonist antibody. Clin Cancer Res 17: 5926-5934.
17. Steinbach D, Onda M, Voigt A, Dawczynski K, Wittig S, et al. (2007) Mesothelin, a possible target for immunotherapy, is expressed in primary AML cells. Eur J Haematol 79: 281-286.
18. Ho M, Bera TK, Willingham MC, Onda M, Hassan R, et al. (2007) Mesothelin expression in human lung cancer. Clin Cancer Res 13: 1571-1575.
19. Hassan R, Bullock S, Premkumar A, Kreitman RJ, Kindler H, et al. (2007) Phase I study of SS1P, a recombinant anti-mesothelin immunotoxin given as a bolus I.V. infusion to patients with mesothelin-expressing mesothelioma, ovarian, and pancreatic cancers. Clin Cancer Res 13: 5144-5149.
20. Hassan R, Bera T, Pastan I, (2004) Mesothelin: a new target for immunotherapy. Clin Cancer Res 10: 3937-3942.
21. Kreitman RJ, Hassan R, Fitzgerald DJ, Pastan I, (2009) Phase I trial of continuous infusion anti-mesothelin recombinant immunotoxin SS1P. Clin Cancer Res 15: 5274-5279.
22. Pastan I, Onda M, Weldon J, Fitzgerald D, Kreitman R, (2011) Immunotoxins with decreased immunogenicity and improved activity. Leuk Lymphoma 52Suppl 2: 87-90.
23. Onda M, Beers R, Xiang L, Lee B, Weldon JE, et al. (2011) Recombinant immunotoxin against B-cell malignancies with no immunogenicity in mice by removal of B-cell epitopes. Proc Natl Acad Sci U S A 108: 5742-5747.
24. Hansen JK, Weldon JE, Xiang L, Beers R, Onda M, et al. (2010) A recombinant immunotoxin targeting CD22 with low immunogenicity, low nonspecific toxicity, and high antitumor activity in mice. J Immunother 33: 297-304.
25. Onda M, Beers R, Xiang L, Nagata S, Wang QC, et al. (2008) An immunotoxin with greatly reduced immunogenicity by identification and removal of B cell epitopes. Proc Natl Acad Sci U S A 105: 11311-11316.
26. Liu XF, FitzGerald DJ, Pastan I, (2013) The insulin receptor negatively regulates the action of Pseudomonas toxin-based immunotoxins and native Pseudomonas toxin. Cancer Res 73: 2281-2288.
27. Risberg K, Fodstad O, Andersson Y, (2011) Synergistic anticancer effects of the 9.2.27PE immunotoxin and ABT-737 in melanoma. PLoS One 6: e24012.
28. Schindler J, Gajavelli S, Ravandi F, Shen Y, Parekh S, et al. (2011) A phase I study of a combination of anti-CD19 and anti-CD22 immunotoxins (Combotox) in adult patients with refractory B-lineage acute lymphoblastic leukaemia. Br J Haematol 154: 471-476.
29. Herrera L, Bostrom B, Gore L, Sandler E, Lew G, et al. (2009) A phase 1 study of Combotox in pediatric patients with refractory B-lineage acute lymphoblastic leukemia. J Pediatr Hematol Oncol 31: 936-941.
30. Zhang Y, Xiang L, Hassan R, Pastan I, (2007) Immunotoxin and Taxol synergy results from a decrease in shed mesothelin levels in the extracellular space of tumors. Proc Natl Acad Sci U S A 104: 17099-17104.
31. Akiyama S, Fojo A, Hanover JA, Pastan I, Gottesman MM, (1985) Isolation and genetic characterization of human KB cell lines resistant to multiple drugs. Somat Cell Mol Genet 11: 117-126.
32. Zhang Y, Chertov O, Zhang J, Hassan R, Pastan I, (2011) Cytotoxic activity of immunotoxin SS1P is modulated by TACE-dependent mesothelin shedding. Cancer Res 71: 5915-5922.
33. Chen W, Bai L, Wang X, Xu S, Belinsky SA, et al. (2010) Acquired activation of the Akt/cyclooxygenase-2/Mcl-1 pathway renders lung cancer cells resistant to apoptosis. Mol Pharmacol 77: 416-423.
34. Wang X, Chen W, Zeng W, Bai L, Tesfaigzi Y, et al. (2008) Akt-mediated eminent expression of c-FLIP and Mcl-1 confers acquired resistance to TRAIL-induced cytotoxicity to lung cancer cells. Mol Cancer Ther 7: 1156-1163.
35. Coloff JL, Macintyre AN, Nichols AG, Liu T, Gallo CA, et al. (2011) Akt-dependent glucose metabolism promotes Mcl-1 synthesis to maintain cell survival and resistance to Bcl-2 inhibition. Cancer Res 71: 5204-5213.
36. Martiny-Baron G, Fabbro D, (2007) Classical PKC isoforms in cancer. Pharmacol Res 55: 477-486.
37. Kuo WL, Liu J, Mauceri H, Vokes EE, Weichselbaum R, et al. (2010) Efficacy of the multi-kinase inhibitor enzastaurin is dependent on cellular signaling context. Mol Cancer Ther 9: 2814-2824.
38. Wu X, Zhu M, Fletcher JA, Giobbie-Hurder A, Hodi FS, (2012) The protein kinase C inhibitor enzastaurin exhibits antitumor activity against uveal melanoma. PLoS One 7: e29622.
39. Andersson Y, Juell S, Fodstad O, (2004) Downregulation of the antiapoptotic MCL-1 protein and apoptosis in MA-11 breast cancer cells induced by an anti-epidermal growth factor receptor-Pseudomonas exotoxin a immunotoxin. Int J Cancer 112: 475-483.